Camrelizumab
- Generic Name
- Camrelizumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1798286-48-2
- Unique Ingredient Identifier
- 73096E137E
- Background
Camrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).
- Indication
⑴用于至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤患者的治疗。
⑵用于霍奇金淋巴瘤（三线）、肝细胞癌（二线）、非鳞状非小细胞肺癌（一线联合）、食管鳞癌（二线）。
⑶用于既往接受过二线及以上化疗后疾病进展或不可耐受的晚期鼻咽癌患者的治疗。
⑷联合顺铂和吉西他滨用于局部复发或转移性鼻咽癌患者的一线治疗。
- Associated Conditions
- -
- Associated Therapies
- -
Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma
- Conditions
- Interventions
- First Posted Date
- 2022-08-23
- Last Posted Date
- 2023-07-20
- Lead Sponsor
- Peking University Cancer Hospital & Institute
- Target Recruit Count
- 40
- Registration Number
- NCT05512481
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Camrelizumab Combined With Cisplatin in the Treatment of Advanced Cutaneous Squamous Cell Carcinoma
- First Posted Date
- 2022-08-05
- Last Posted Date
- 2023-11-08
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05490485
- Locations
- 🇨🇳
Department of Bone and Soft Tissue ,Henan Cancer Hospital, Zhengzhou, Henan, China
Neoadjuvant Therapy of Camrelizumab Combined With Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
- First Posted Date
- 2022-07-27
- Last Posted Date
- 2022-07-27
- Target Recruit Count
- 39
- Registration Number
- NCT05476380
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute & Hospital, Tianjin, China
Camrelizumab Combination With SBRT and Concurrent Chemotherapy Treated Stage IV Oligometastatic Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-07-25
- Last Posted Date
- 2022-07-25
- Lead Sponsor
- Sichuan Cancer Hospital and Research Institute
- Target Recruit Count
- 35
- Registration Number
- NCT05472467
- Locations
- 🇨🇳
Sichuan Cancer Hospital & Institute, Chengdu, Sichuan, China
Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-07-18
- Last Posted Date
- 2022-07-18
- Lead Sponsor
- China Medical University, China
- Target Recruit Count
- 1
- Registration Number
- NCT05461235
Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
- Conditions
- Interventions
- First Posted Date
- 2022-07-07
- Last Posted Date
- 2023-05-22
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 35
- Registration Number
- NCT05447702
- Locations
- 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China
A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-06-30
- Last Posted Date
- 2022-06-30
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 70
- Registration Number
- NCT05438706
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Real World Study of Camrelizumab in the Treatment of Advanced Non-squamous Non-small-cell Lung Cancer
- First Posted Date
- 2022-05-24
- Last Posted Date
- 2023-07-20
- Lead Sponsor
- Affiliated Hospital of Nantong University
- Target Recruit Count
- 100
- Registration Number
- NCT05387512
- Locations
- 🇨🇳
Department of Pharmacy, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China
A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
- Conditions
- Interventions
- First Posted Date
- 2022-05-10
- Last Posted Date
- 2023-08-22
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 251
- Registration Number
- NCT05367687
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
Camrelizumab Combined With Apatinib Versus Apatinib Alone in the Third-line Treatment of Metastatic Gastric Cancer
- First Posted Date
- 2022-04-22
- Last Posted Date
- 2022-04-22
- Target Recruit Count
- 68
- Registration Number
- NCT05342389
- Locations
- 🇨🇳
The Sixth Affiliated hosipital, Sun Yat-Sen University, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.